Abstract
Chemotherapy-induced multi-drug resistance (MDR) in tumors poses a huge challenge for clinical treatment of tumors. The downregulation of the multi-drug resistance relative protein, represented by P-glycoprotein (P-gp), can reverse MDR of cancer cells. In this study, we developed doxorubicin-loading nanocarrier based on the assembly of protein and antisense oligonucleotide (ASO) to combat MDR of cancer cells. The data demonstrate that the nanocarrier can efficiently deliver ASO to cytoplasm and downregulate the P-glycoprotein expression, subsequently improving the therapeutic effects of Dox in doxorubicin-resistant MCF-7/ADR cancer cells. The preparation is simple and effective, providing a powerful tool for gene delivery. Therefore, our nanocarrier shows high promise in cancer treatment.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Int J Cancer, 2015, 136: E359–E386
Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LKF, Wong WD, Paty PB. J Clin Oncol, 2009, 27: 3379–3384
Eisenkop SM, Spirtos NM, Friedman RL, Lin WCM, Pisani AL, Perticucci S. Gynecol Oncol, 2003, 90: 390–396
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. N Engl J Med, 2002, 347: 1233–1241
Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wigkerham DL, Wolmark N, Fisher ER, Margolese R, Sutherland C, Glass A, Foster R, Caplan R. N Engl J Med, 1989, 320: 473–478
Goodman LS. J Am Med Assoc, 1946, 132: 126–132
Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U. N Engl J Med, 1976, 294: 405–410
Stillman B. Science, 1996, 274: 1659–1663
Amaral N, Vendrell A, Funaya C, Idrissi FZ, Maier M, Kumar A, Neurohr G, Colomina N, Torres-Rosell J, Geli MI, Mendoza M. Nat Cell Biol, 2016, 18: 516–526
Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava DK, Leisenring WM, Neglia JP, Sklar CA, Kaste SC, Hudson MM, Diller LR, Stovall M, Donaldson SS, Robison LL. Pediatr Blood Cancer, 2014, 61: 53–67
Green DM, Liu W, Kutteh WH, Ke RW, Shelton KC, Sklar CA, Chemaitilly W, Pui CH, Klosky JL, Spunt SL, Metzger ML, Srivastava DK, Ness KK, Robison LL, Hudson MM. Lancet Oncology, 2014, 15: 1215–1223
Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, El Sabeh R, Perez-Pineiro R, Wishart DS, Cohen R, Tuszynski J, Dumontet C. Mol Pharmacol, 2013, 84: 12–24
Romain S, Martin PM, Klijn JGM, van Putten WLJ, Look MP, Guirou O, Foekens JA. Int J Cancer, 1997, 74: 156–161
Booser DJ, Hortobagyi GN. Drugs, 1994, 47: 223–258
Basso AD, Solit DB, Munster PN, Rosen N. Oncogene, 2002, 21: 1159–1166
Dassonneville L, Lansiaux A, Wattelet A, Wattez N, Mahieu C, Van Miert S, Pieters L, Bailly C. Eur J Pharmacol, 2000, 409: 9–18
Dassonneville L, Bonjean K, De Pauw-Gillet MC, Colson P, Houssier C, Quetin-Leclercq J, Angenot L, Bailly C. Biochemistry, 1999, 38: 7719–7726
Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quirós JR, Roddam A, Thiebaut A, Tjønneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E. J Natl Cancer Inst, 2005, 97: 755–765
Villena-Heinsen C, Diesing D, Fischer D, Griesinger G, Maas N, Diedrich K, Friedrich M. Anticancer Res, 2006, 26: 4817–4823
Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Int J Radiat Oncol, 2004, 58: 786–796
Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE, Higgins CF. Nature, 1990, 346: 362–365
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Proc Natl Acad Sci USA, 1987, 84: 7735–7738
Gottesman MM, Fojo T, Bates SE. Nat Rev Cancer, 2002, 2: 48–58
Dönmez Y, Akhmetova L, İşeri ÖD, Kars MD, Gündüz U. Cancer Chemoth Pharm, 2011, 67: 823–828
Zgurskaya HI, Nikaido H. Mol Microbiol, 2000, 37: 219–225
Ling V. Cancer Chemoth Pharm, 1997, 40: S3–S8
Krishna R, Mayer LD. Eur J Pharm Sci, 2000, 11: 265–283
Conde J, Oliva N, Artzi N. Proc Natl Acad Sci USA, 2015, 112: E1278–E1287
Mo R, Jiang T, DiSanto R, Tai W, Gu Z. Nat Commun, 2014, 5: 1–10
Sorgi FL, Bhattacharya S, Huang L. Gene Ther, 1997, 4: 961–968
Acknowledgments
This work was supported by the National Natural Science Foundation of China (21325520, 21327009, 21405041, J1210040), the Foundation for Innovative Research Groups of National Natural Science Foundation of China (21521063), and the Science and Technology Project of Hunan Province (2016RS2009, 2016WK2002).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Yu, X., Gong, L., Zhang, J. et al. Nanocarrier based on the assembly of protein and antisense oligonucleotide to combat multidrug resistance in tumor cells. Sci. China Chem. 60, 1318–1323 (2017). https://doi.org/10.1007/s11426-017-9108-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11426-017-9108-5